SecProbe.io

Mail Stop 4720

March 7, 2016

Jon P. Stonehouse
President and Chief Executive Officer
BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd., Suite 200
Durham, North Carolina 27703

Re: BioCryst Pharmaceuticals, Inc.
  Post-Effective Amendment No.  1 to Registration Statement on Form S-3
Filed  February 26, 2016
  File No.  333-202466

Dear Mr. Stonehouse :

We have limited our review of your post-effective amendment  to the issue addressed in
our comment. Please respond to this letter by amending your registration statement or otherwise
providing the requested information . If you do not believe our comment appl ies to yo ur facts and
circumstances or do not believe an amendment is appropriate, please tell us why in a response.

After reviewing any amendment to your registration statement and any information you
provide in response to these  comments, we may have  additiona l comments.

Incorporation of Certain Documents by Reference, page 17

1. We note that you incorporate by reference your Annual Report on Form 10 -K for the year
ended December 31, 2015. However, the Form 10 -K incorporates by reference
information from your definitive proxy statement that has not yet been filed. Please note
that we will not be in a position to take your filing effective until you have amended the
Form 10 -K to include Part III information or filed the definitive proxy statement. Please
refer to Compliance and Disclosure Interpretations, Securities Act Forms, Question
123.01 and Regulation S -K, Question 117.05 for guidance.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure
in the filing to be certain that the filing includes the information the Secur ities Act of 193 3 and
all applicable Securities  Act rules require.   Since the company and its management are in
possession of all facts relating to a company’s disclosure, they are responsible for the accuracy
and adequacy of the disclosures they have made .

Jon P. Stonehouse
BioCryst Pharmaceuticals, Inc.
March 7, 2016
Page 2

 Notwithstanding our comment , before we can declare the amended registration statement
effective, the company should provide us with a letter, acknowledging that:

 should the Commission or the staff, acting pursuant to delegated authority, declare the
filing effective, it does not foreclose the Commission from taking any action with respect
to the filing;

 the action of the Commission or the staff, acting pursuant to delegated authority, in
declaring the filing effective, does not relieve the company fr om its full responsibility for
the adequacy and accuracy of the disclosure in the filing; and

 the company may not assert staff comments and the declaration of effectiveness as a
defense in any proceeding initiated by the Commission or any person under th e federal
securities laws of the United States.

Please contact Scot Foley  at (202) 551 -3383  or Mary Beth Breslin  at (202) 551 -3625  with
any questions.

Sincerely,

 /s/ Mary Beth Breslin for

Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance

cc:  Brian Lane, Esq.